Holen Sie sich die Stockscreener-App
133.38
1.58%
-2.135
Schlusskurs vom Vortag:
$135.52
Offen:
$135.24
24-Stunden-Volumen:
266.49K
Relative Volume:
0.54
Marktkapitalisierung:
$4.26B
Einnahmen:
$560.03M
Nettoeinkommen (Verlust:
$-150.66M
KGV:
-27.45
EPS:
-4.86
Netto-Cashflow:
$-87.43M
1W Leistung:
-0.40%
1M Leistung:
-8.48%
6M Leistung:
+20.39%
1J Leistung:
+34.71%
1-Tages-Spanne:
$132.21
$135.46
1-Wochen-Bereich:
$132.21
$138.85
52-Wochen-Spanne:
$55.92
$157.13
Irhythm Technologies Inc Stock (IRTC) Company Profile
Firmenname
Irhythm Technologies Inc
Sektor
Branche
Telefon
415-632-5700
Adresse
699 8TH STREET, San Francisco, CA
Vergleichen Sie IRTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRTC
Irhythm Technologies Inc
|
133.38 | 4.28B | 560.03M | -150.66M | -87.43M | -4.86 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Irhythm Technologies Inc Stock (IRTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-03 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-06-20 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-07 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-04-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-02-24 | Hochstufung | Needham | Hold → Buy |
| 2022-01-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-12 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-11 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-12-21 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-06-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-04-13 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-04-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Colliers Securities | Buy → Neutral |
| 2021-01-29 | Bestätigt | Needham | Hold |
| 2020-11-17 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-09-11 | Eingeleitet | Needham | Hold |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Neutral |
| 2020-08-07 | Hochstufung | Colliers Securities | Neutral → Buy |
| 2020-08-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-10 | Eingeleitet | William Blair | Outperform |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-10-22 | Eingeleitet | Oppenheimer | Perform |
| 2019-02-20 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-09-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-09-06 | Eingeleitet | Chardan Capital Markets | Buy |
| 2018-08-02 | Hochstufung | Dougherty & Company | Sell → Neutral |
| 2018-07-16 | Herabstufung | Dougherty & Company | Neutral → Sell |
| 2017-12-01 | Eingeleitet | Dougherty & Company | Neutral |
Alle ansehen
Irhythm Technologies Inc Aktie (IRTC) Neueste Nachrichten
iRhythm Technologies Inc. Stock Analysis and ForecastBreakout stock performance - jammulinksnews.com
Is iRhythm Technologies Inc. a good long term investmentOutstanding capital growth - jammulinksnews.com
What analysts say about iRhythm Technologies Inc. stockUnstoppable trading performance - jammulinksnews.com
What drives iRhythm Technologies Inc. stock priceTremendous gains - Autocar Professional
Would iRhythm Technologies (NASDAQ:IRTC) Be Better Off With Less Debt? - simplywall.st
1 Russell 2000 Stock Worth Your Attention and 2 Facing Challenges - Yahoo Finance
Sanofi India Limited (SANOFI) Hits 52 Week HighOutstanding risk-reward balance - Autocar Professional
TEM Shares Surge on New AI Breakthrough: Should Investors Jump In? - MSN
iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025 - The Manila Times
ECG Sensor Patches Market worth $2.32 billion by 2032 with 12.0% CAGR | MarketsandMarkets™ - PR Newswire
Robert W. Baird Maintains Buy Rating on Irhythm Technologies with $160 Price Target - AInvest
(IRTC) Technical Data - news.stocktradersdaily.com
IRHYTHM INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc.IRTC - Eastern Progress
Global Mobile ECG Devices Market Set for Rapid Expansion at 11.7% CAGR by 2032 | AliveCor, Beurer UK Ltd., Omron - The Globe and Mail
Researchers Find Wearables Help Detect Post-Op AFib - Diagnostic and Interventional Cardiology
1 Healthcare Stock on Our Buy List and 2 to Brush Off - Yahoo Finance
iRhythm Technologies (IRTC): Analyst Maintains Optimistic Outloo - GuruFocus
iRhythm (IRTC) Stock Trades Up, Here Is Why - Yahoo Finance
Wearable Blood Pressure Monitoring Patches Market CAGR 9.56% - openPR.com
Global Artificial Intelligence (AI) in Remote Patient - openPR.com
5 Revealing Analyst Questions From iRhythm’s Q1 Earnings Call - Yahoo Finance
Medical Device Leader with 40-Year Track Record and 6 Patents Joins Integer Board - Stock Titan
IRhythm Argues Patent Owner's Inaction Shouldn't Doom IPRs - Law360
iRhythm Technologies Announces Board Member Changes - The Globe and Mail
IRhythm IPR Denial Raises Key PTAB Discretion Questions - Law360
GameSquare (GAME) files equity & warrant offering; crypto plan flagged | IRTC SEC FilingForm 8-K - Stock Titan
iRhythm Technologies announces board changes as two directors retire - Investing.com Australia
iRhythm Urges Stewart to Reconsider and Clarify ‘Settled Expectations’ Basis for Discretionary Denial - IPWatchdog.com
iRhythm Technologies Announces Board Member Retirements and New Director Appointments | IRTC Stock News - GuruFocus
iRhythm Technologies Announces Board Member Retirements and New Director Appointments - The Manila Times
iRhythm Technologies Announces Retirement of Board Members and Appointment of New Directors - Quiver Quantitative
iRhythm Technologies Makes Crucial Board Changes: Two Veterans Exit as Digital Health Experts Step In - Stock Titan
IPR Denial In IRhythm Should Not Set A Blanket Rule - Law360
Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 8, 2024 in iRhythm Technologies Lawsuit – IRTC - ACCESS Newswire
Top 10 Healthcare AI Stocks to Buy According to Hedge Funds - Insider Monkey
IRTC SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds iRhythm Technologies, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Reach Out - ACCESS Newswire
ECG Sensor Patches Market Growth, Drivers, and Opportunities - MarketsandMarkets
Smart Wearable ECG Monitors Market Latest Published Study 2025 - InsightAce Analytic
Patient Monitoring Stocks Q1 In Review: iRhythm (NASDAQ:IRTC) Vs Peers - Yahoo Finance
Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc.IRTC - FinancialContent
Discretionary Denial Rulings May Spur Calls For PTAB Reform - Law360
Investor Network: iRhythm Technologies, Inc. to Host Earnings Call - ACCESS Newswire
User - FinancialContent
(IRTC) Trading Report - news.stocktradersdaily.com
Study Highlights Burden, Risk of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease - Diagnostic and Interventional Cardiology
Finanzdaten der Irhythm Technologies Inc-Aktie (IRTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):